11 unchanged sentences
Purchased Under
−Removed: April 1, 2023 - April 30, 2023 1,006 (1)
+Added: July 1, 2023 - July 31, 2023 1,132 (1)
— $4,808,991,028
−Removed: May 1, 2023 - May 31, 2023 1,105 (1)
+Added: August 1, 2023 - August 31, 2023 984 (1)
— $4,808,991,028
−Removed: June 1, 2023 - June 30, 2023 1,194 (1)
+Added: September 1, 2023 - September 30, 2023 1,059 (1)
— $4,808,991,028
1 unchanged sentence
— $4,808,991,028 (2)
−Removed: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,006 in April;
−Removed: 1,105 in May;
−Removed: and 1,194 in June.
+Added: In addition to AbbVie shares repurchased on the open market under a publicly announced program, if any, these shares also included the shares purchased on the open market for the benefit of participants in the AbbVie Employee Stock Purchase Plan – 1,132 in July;
+Added: 984 in August;
+Added: and 1,059 in September.
On February 16, 2023, AbbVie’s board of directors authorized a $5.0 billion increase to the existing stock repurchase authorization.
1 unchanged sentence
(c) Director and Officer Trading Arrangements
−Removed: During the three months ended June 30, 2023, no director or officer of the company adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
+Added: During the three months ended September 30, 2023, no director or officer of the company adopted , modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.
2023 Form 10-Q |
1 unchanged sentence
Exhibit Description
+Added: Amendment to the AbbVie 2013 Performance Incentive Plan.
Certification of Chief Executive Officer Required by Rule 13a-14(a) (17 CFR 240.13a-14(a)).
5 unchanged sentences
101 The following financial statements and notes from the AbbVie Inc.
−Removed: Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, filed on August 7, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language):
+Added: Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, filed on November 6, 2023, formatted in iXBRL (Inline eXtensible Business Reporting Language):
(i) Condensed Consolidated Statements of Earnings;
7 unchanged sentences
_______________________________________________________________________________
+Added: * Denotes management contract or compensatory plan or arrangement required to be filed as an exhibit hereto.
2023 Form 10-Q |
2 unchanged sentences
Chief Financial Officer (Principal Financial Officer)
−Removed: August 7, 2023
+Added: November 6, 2023
2023 Form 10-Q |
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.